A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.
Inclusion Criteria:
Exclusion Criteria:
-Evidence of untreated or inadequately treated latent or active TB.
Novosibirsk, 630099, Russia
Orenburg, 460000, Russia
Petrozavodsk, 185910, Russia
Smolensk, 214019, Russia
Kharkiv, 61058, Ukraine
Kyiv, 02081, Ukraine
Kyiv, 03680, Ukraine
M. Ivano-Frankivsk, 76018, Ukraine
Odesa, 65026, Ukraine
Vinnytsia, 21028, Ukraine